Systemic antifungals. Pharmacodynamia and pharmacokinetics;Antifúngicos sistémicos. Farmacodinamia y farmacocinética

Revista Iberoamericana de Micologia

Volumn 23, Issue 1, 2006, Pages 39-49

  Catalán, Mercedes ^a   Montejo, Juan Carlos ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Antifungal Drugs; Invasive fungal infection; New drugs

Indexed keywords

ALBACONAZOLE; AMINOCANDIN; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CANADIOL; CARBAMAZEPINE; CASPOFUNGIN; CIDOFOVIR; CISPLATIN; CYCLOSPORIN A; DIGITALIS; FLUCONAZOLE; FLUCYTOSINE; FOSCARNET; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; PENTAMIDINE; POSACONAZOLE; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; RITONAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE; ZIDOVUDINE;

BONE MARROW TOXICITY; CRITICALLY ILL PATIENT; DIARRHEA; DRUG FORMULATION; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHARMACODYNAMICS; REVIEW; VOMITING;

EID: 32644435914     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(06)70012-2     Document Type: Review

References (68)

1. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49 (Suppl 1): 21-30.
2. Arikan S, Rex JH. Lipid-based antifungal agents: current status. Curr Pharm Des 2001; 7: 393-415.
3. Arikan S, Rex JH. New agents for the treatment of systemic fungal infections: current status. Expert Opin Emerg Drugs 2002; 7: 3-32.
4. Arikan S, Rex JH. Ravuconazole Eisai/Bristol-Myers Squibb. Curr Opin Investig Drugs 2002; 3: 555-561.
5. Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, Cui D, Kari PH, Ly T, Hop CE, Singh R, Wallace MA, Dean DC, Lin JH, Pearson PG, Baillie TA. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000; 28: 1274-1278.
6. Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG, Hawkey PM, Herbrecht R, Marks DI, Moraleda JM, Park GR, Senn SJ, Viscoli C; Amphotericin B Systematic Review Study Group. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295-1320.
7. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, Dasbach EJ, Platt R. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693.
8. Beck-Sague CM, Jarvis WR. The National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United Stated. J Infect Dis 1993; 167: 1247-1251.
9. Bennett JE. Salvage therapy for aspergillosis. Clin Infec Dis 2005; 41 (Suppl 6): S387-S388.
10. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2020.
11. Carrillo-Muñoz AJ, Cárdenas CD, Carrillo-Orive B, Rodríguez V, del Valle O, Casals JB, Ezkurra PA, Quindós G. In vitro antifungal activity of voriconazole against dermatophytes and superficial isolates of Scopulariopsis brevicaulis. Rev Iberoam Micol 2005; 22: 110-113.
12. Chandrasekar PH, Manavathu EK. Caspofungin. Drugs Today 2002; 38: 829-846.
13. Chen A, Sobel JD. Emerging azole antifungals. Expert Opin Emerg Drugs 2005; 10: 21-33.
14. Cornely OA, Schmitz K, Aisen brey S. The first echinocandin: caspofungin. Mycoses 2002; 3: 56-60.
15. Corno JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-272.
16. De Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, Diekmann-Berndt H. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-849.
17. de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E, Llanos EA, Fisco C, Lau W, Buell D. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21: 899-907.
18. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-1457.
19. Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr Clin Top Infect Dis 2000; 20: 1-23.
20. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-136.
21. Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17: 159-191.
22. Groll AH, Stergiopoulou T, Roilides E, Walsh TJ. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs 2005; 14: 489-509.
23. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10: 1545-1558.
24. Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005; 45: 1145-1152.
25. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
26. Herbrecht R, Natarajan-Ame S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003; 4: 1277-1287.
27. Herbrecht R, Nivoix Y, Fohrer C, Natarajan-Ame S, Letscher-Bru V. Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother 2005; 56 (suppl) 1: i39-i48.
28. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004; 58: 612-624.
29. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther 2004; 2: 485-497.
30. Higashiyama Y, Kohno S. Micafungin: a therapeutic review. Expert Rev Anti Infect Ther 2004; 2: 345-355.
31. Hoffman HL, Ernst EJ, Klepser ME. Novel triazole antifungal agents. Expert Opin Investig Drugs 2000; 9: 593-605.
32. Johnson LB, Kauffman CA. Voriconazole. A new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637.
33. Kale P, Johnson LB. Second-generation azole antifungal agents. Drugs Today 2005; 41: 91-105.
34. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T; Anidulafungin Invasive Candidiasis Study Group. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48: 2021-2024.
35. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-775.
36. Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51: 513-521.
37. Matthews R, Burnie J. Antifungal antibodies: a new approach to the treatment of systemic candidiasis. Curr Opin Investig Drugs 2001; 2: 472-476.
38. Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 2004; 22: 865-871.
39. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, Illidge C, Burnie J. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003; 47: 2208-2216.
40. Mellado E, Cuenca-Estrella M, Rodríguez-Tudela JL. Clinical relevante of mechanisms of antifungal drug resistance in filamentous fungi. Enferm Infecc Microbiol Clin 2003; 20: 523-529.
41. Mora-Duarte J, Betts R, Rotstein C, Lopes Colombo A, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect, for the Caspofungin Invasive Candidiasis Study Group Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
42. Morera López Y, Torre-Rodríguez JM, Jiménez Cabello T. Estudio de la sensibilidad in vitro de aislamientos clínicos de mohos y levaduras a itraconazol y voriconazol. Rev Iberoam Micol 2005; 22: 105-109.
43. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "Gold Standard". Clin Infect Dis 2003; 37: 415-425.
44. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003; 16: 533-537.
45. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38; 161-189.
46. Parnham MJ, Bogaards JJ, Schrander F, Schut MW, Oreskovic K, Mildner B. The novel antifungal agent PLD-118 is neither metabolized by liver microsomes nor inhibits cytochrome P450 in vitro. Biopharm Drug Dispos 2005; 26: 27-33.
47. Patel R. Antifungal agentes. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc 1998; 73: 1205-1225.
48. Petraitis V, Petraitiene R, Kelaher AM, Sarafandi AA, Sein T, Mickiene D, Bacher J, Groll AH, Walsh TJ. Efficacy of PLD-118, a novel inhibitor of Candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. Antimicrob Agents Chemother 2004; 48: 3959-3967.
49. Quindós G, Ruesga MT, Martín-Mazuelos E, Salesa R, Alonso-Vargas R, Carrillo-Muñóz AJ, Brena S, San Millán R, Pontón J. In vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts. Rev Iberoam Micol. 2004; 21: 63-69.
50. Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2004; 2: 499-508.
51. Rex JH, Walsh TJ, Sobel JG, Filler SG, Pappas PG, Dismukes WE, Edwards JE. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-678.
52. Saag MS, Graybill RJ, Iarsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710-718.
53. Schwesinger G, Junghans D, Schroder G, Bernhardt H, Knoke M. Candidosis and aspergillosis as autopsy findings from 1994 to 2003. Mycoses 2005; 48: 176-180.
54. Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am 2005; 52: 895-915.
55. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696-709.
56. Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22: 24-28.
57. Terrell CL. Antifungal agents. Part II. The azoles. Mayo Cin Proc 1999; 74: 78-100.
58. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23: 805-812.
59. Thomson AH, Shankland G, Clareburt C, Binning S. Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration. Intensive Care Med 2002; 28: 999.
60. Van Burik JA. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis 2005; 18: 479-483.
61. Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 2005; 27: 657-673.
62. Walsh TJ. Echinocandins-an advance in the primary treatment of invasive candidiasis. N Engl J Med 2002; 347: 2070-2072.
63. Warn PA, Sharp A, Morrissey G, Denning DW. In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother 2002; 50: 1071-1074.
64. Wenzel RP. John E Bennett Forum on Deep Mycoses Study Desing 2004: Candidiasis and salvage therapy for aspergillosis: introduction. Clin Infect Dis 2005; 41 (Suppl 6): S369-S370.
65. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-1534.
66. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603-618.
67. Yeates C. Icofungipen (PLIVA). Curr Opin Investig Drugs 2005; 6: 838-844.
68. Zaas AK, Steinbach WJ. Micafungin: the US perspective. Expert Rev Anti Infect Ther 2005; 3: 183-190.